Friday, April 17, 2015 4:26:34 PM
Gilead looks like they went after one of Avids employees.... for losing out on Michael Molony to Avid.
-------
April Loui
Director, CMC Clinical Quality at Gilead Sciences
Director, CMC Clinical Quality
Gilead Sciences
November 2014 – Present (6 months)
Director, Quality
Avid Bioservices
October 2011 – October 2014 (3 years 1 month)
..
..
https://www.linkedin.com/in/awloui
--------------
Michael Molony
Director at Avid Bioservices
Summary
BIOTECHNOLOGY SCIENTIST & DIRECTOR
Results-driven, goal-oriented Biotechnology Scientist and Manager with over 25 years of broad-based management experience in contemporary laboratory operations, advanced analytical and experimental procedures, and the effective support of successful biotechnology development efforts. Strong working knowledge of modern analytical methodologies, automation systems, and statistical experimental design techniques. Exceptional ability to concurrently manage complex, multi-step laboratory experiments while meeting rigorous procedural standards, tight time-frames, and design/write/execute operational protocols. Over 10 years of GMP laboratory experience with a proven track record of successful regulatory inspections.
Technical Experience Key Words:
HPLC, microsequencing, amino acid analysis, Gel Imaging, Electroblotting, Binding Kinetic studies, peptide synthesis, carbohydrate analysis, MALDI-TOF, ESI-MS, ELISAs, Robotic Liquid handling, capillary electrophoresis, residual process impurities, cloning, blotting, sequencing, restriction mapping, BSL-3 room, automated cycle sequencing.
Certifications: PMP, Agilent Chem Station Plus CDS Administrator, LabWare LIMS system Administrator I & II, JMP, SIMPCA-P (Multivariate Analysis), Stat-Ease DOE Software, FOSS NIR Software, Waters Empower CDS Administrator I & II.
Memberships: CaSSS, ACS, PDA, ASQ
Experience
Avid Bioservices
Director
Avid Bioservices
July 2013 – Present (1 year 10 months)Orange County, California Area
Responsible for identification and transition of new products and technologies into the Quality Control laboratories to increase capability and capacity. Overhaul raw materials processes and improve in house raw material testing capability. Lead Avid QC method transfer and validation efforts for high profile client for Phase III/Commercial lauch.
Managed daily QC operations for a contract manufacturing service. Responsibilities included process improvement to streamline the department with the concepts of lean manufacturing and six sigma processes. Oversight of greater than 4 clients release and stability testing services. Oversee QC service offerings to include client method development, validation and expanded in-house raw materials testing. Actively looked for and engaged potential new clients with Business Development group to grow business. Modernized the QC laboratories with equipment upgrades as well as transitioning lab toward a paperless laboratory.
•Led team of 15 for raw materials, lot release and stability testing for several high profile clients
•Team member involved in providing input into ‘Request for Information’ and ‘Request for Proposal’ for prospective clients.
•Sponsored six sigma, lean manufacturing and continuous improvement efforts to streamline daily operations in QC
•Participated in Peregrine Pharmaceuticals CMC team as a consultant/individual contributor for lead Phase III candidate
•Overhauled QC Stability program: SOP Improvement; OOS and OOT procedures to include relevant statistical analysis criteria and outlier detection, Stability SOP to reflect current ICH guidelines, increase internal capability by expanding 'submission ready' stability reports for clients as well as increase storage solutions meeting all four world climactic zones for liquid dose formulations
Gilead Sciences
Associate Director of Analytical Development & Quality Control
Gilead Sciences
March 2012 – June 2013 (1 year 4 months)Oceanside, CA
Oversite of Gileads Biologics Analytical Development and Quality Control. Part of a team for Gilead biologics development, manufacturing and quality centered out of Oceanside, California, that produces Pre-clinical to Phase II clinical material supplies. Team identifies Phase III and commercial supply CMO and performs technology transfer to CMOs. Responsiblity in all regulatory filings in the areas of characterization as well as DS and DP release and stability.
• CMC Responsibilities
• Analytical Development CMC team representative for phase III new biologic entity (Simtuzumab)
•Oversight of AD CMC representative on two early stage products
•Review of all biologics regulatory filings
•Management Responsibilities: Head the Analytical Development and Quality Control departments to support all Gilead development and quality control activities for all Gilead Biologic molecules.
•Successfully led QC team through state board inspection for site licensure.
•Ensured personnel were properly trained and operating in a compliant manner in GMP laboratories.
•Ensured that internal and contract testing laboratories are in compliance with Gilead SOPs and standards.
•Participated in technical assessments of CMOs and participate as an SME in quality audits as requested and later managed Analytical Method Technology Transfer to CMOs.
•Responsible for drug substance release of early phase clinical trial material manufactured in the Oceanside facility.
..
...
..
https://www.linkedin.com/pub/michael-molony/5/7a8/bb5
---------------------
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!
Recent CDMO News
- Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance • GlobeNewswire Inc. • 05/23/2024 12:05:46 PM
- Avid Bioservices to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 08:05:11 PM
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
- Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 03/06/2024 09:31:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:57:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 12:34:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:39:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:38:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:37:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:36:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:35:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 12:56:02 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/08/2024 09:32:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:56:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:55:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:53:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:51:57 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 12/19/2023 09:05:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:34:08 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM